Nebivolol Krka

Nebivolol, the active ingredient in Nebivolol Krka, is a beta blocker presented as an oral tablet for oral use. It treats hypertension and heart failure in adult patients by lowering blood pressure and improving cardiac function through selective β1‑adrenergic antagonism and nitric oxide‑mediated vasodilation.

GNH USA supplies Nebivolol Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets. The product meets EU quality standards and is manufactured under strict Good Manufacturing Practices.

Nebivolol is indicated for conditions within the cardiovascular disease pathway, primarily hypertension and heart failure.

- Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications. - Heart failure: improves left ventricular ejection fraction and reduces symptoms of chronic heart failure. - Left ventricular dysfunction: supports cardiac remodeling and functional capacity.

Nebivolol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Fatigue: generalized tiredness that may lessen with continued use. - Nausea: occasional stomach upset or queasiness. - Bradycardia: slower than normal heart rate, usually asymptomatic. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Atrioventricular block: impaired electrical conduction between atria and ventricles. - Bronchospasm: narrowing of airways, particularly in patients with asthma or COPD. - Allergic reactions: rash, itching, or swelling that may indicate hypersensitivity. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Hypotension: dangerously low blood pressure leading to fainting.

Before initiating Nebivolol therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

- Blood pressure monitoring: ensure adequate control without excessive hypotension. - Cardiac assessment: review baseline heart rate and conduction abnormalities. - Concomitant beta‑blockers: avoid additive effects that may cause severe bradycardia. - Respiratory disease: use caution in asthma or chronic obstructive pulmonary disease. - Hepatic or renal impairment: consider dose adjustment and close monitoring. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other beta‑blockers: combined use may cause profound bradycardia and hypotension. - Non‑dihydropyridine calcium channel blockers (verapamil, diltiazem): increase risk of atrioventricular block. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): raise nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely):\n- Diuretics: additive blood‑pressure‑lowering effect, monitor for orthostatic changes. - ACE inhibitors or ARBs: may enhance antihypertensive response, watch for excessive hypotension. - Anti‑arrhythmic agents (e.g., amiodarone): potential for heart‑rate disturbances. - NSAIDs: may blunt antihypertensive effect, assess blood‑pressure control. - Insulin or oral hypoglycemics: nebivolol can mask hypoglycemia symptoms, monitor glucose levels.